UnknownPhase 1

The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma

China60 participantsStarted 2020-08-01

Plain-language summary

The small insulinoma can not be detected by the CT or MRI. We use 68Ga-NOTA-exendin-4 positron emission tomography/computed tomography (PET/CT) to detect the insulinoma for the patient diagnosed with endogenous hyperinsulinemic hypoglycaemia. And the diagnostic value will be performed. A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously. Visual and semiquantitative method will be used to assess the PET/CT images.

Who can participate

Age range6 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 1.age ≥6 years old 2.Patients with hypoglycaemia 3.Endogenous hyperinsulinemic hypoglycaemia 4.Enhanced CT or MRI within 1 month 5.Signed written consent Exclusion Criteria: * 1\. Breast feeding 2.Pregnancy or the wish to become pregnant within 6 months 3.Renal function: serum creatinine during 41-73umol/L 4.Any medical condition may significantly interfere with study compliance; 5.Known allergy

What they're measuring

Standard uptake value (SUV)

Timeframe: From right after tracer injection to 1-hours post-injection

Trial details

NCT IDNCT04979611

SponsorFirst Affiliated Hospital of Fujian Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-08-01

Contact for this trial

weibing miao, MD

86-0591-87981618 miaoweibing@126.com

View on ClinicalTrials.gov More Insulinoma trials